Abstract 782
Background
Cell fusion (CF) is a normal biological process that plays major role in mammalian development and differentiation. Through CF, somatic cells acquire nuclear reprogramming and epigenetic modifications to form pluripotent hybrid cells, which constitute an efficient process of rapid evolution to generate hybrids with new genetic, phenotypic and functional properties at a rate exceeding that achievable by random mutagenesis. Experimental and clinical evidences indicate that CF occurs in solid tumors and contribute to cancer progression by generating progeny with metastatic features and resistance to oncologic treatments. Phosphatidylserine (PS) is a glycerophospholipid, recognized by CD36 receptor in macrophage to detect apoptotic cells. The PS-CD36 interaction is a crucial step in fusion between monocytes and tumor cells. The aim of this study is to investigate the impact of the PS-CD36 expression in macrophage–cancer cell fusion and in relation to ionizing radiation (IR).
Methods
GFP-labeled breast cancer MCF-7 cells and macrophages (differentiated monocyte cell line THP-1) were used in CF in vitro experiment with IR (figure 1). MCF-7/macrophage hybrids were generated by spontaneous CF, isolated by fluorescence activated cell sorting and confirmed by fluorescence microscopy. We treated the hybrids and their maternal cells (MCF-7 and macrophages) with IR (ɣ-irradiation, 0Gy, 2.5Gy and 5Gy). Anti-CD36 antibody, 40µg and 80µg, was used to block CD36 receptor. CF rate is based on the number of seeded macrophages, since they do not proliferate. The proportion of hybrids = (number of hybrids/number of seeded macrophages in same sample) x100.
Results
IR induces the exposure of PS (dose dependent) on MCF-7 cells, which was not found in macrophages. IR also induces significant expression of CD36 in THP-1 cells. CF was inhibited by blocking of CD36 receptor with anti-CD36 antibodies (figure 2).
Conclusions
IR induces macrophage-cancer cell fusion by stimulating the exposure of PS on MCF-7 cells and the expression of CD36 in macophages. CF and the generation of metastatic hybrids can be prevented by inhibiting the PS-CD36 interaction, a mechanism constituting an essential step in macrophage-cancer CF.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ivan Shabo, Karolinska Institutet, Stockholm Sweden.
Funding
Swedish Society of Medicine.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract